scispace - formally typeset
P

Paolo Brunetti

Researcher at University of Perugia

Publications -  198
Citations -  10690

Paolo Brunetti is an academic researcher from University of Perugia. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 56, co-authored 198 publications receiving 10376 citations.

Papers
More filters
Journal ArticleDOI

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

TL;DR: Glargine is a peakless insulin, it lasts nearly 24 h, it has lower intersubject variability than NPH and ultralente, and it closely mimics CSII, the gold standard of basal insulin replacement.
Journal ArticleDOI

Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension: The PIUMA Study

TL;DR: In untreated subjects with essential hypertension, raised uric acid is a powerful risk marker for subsequent cardiovascular disease and all-cause mortality.
Journal ArticleDOI

Abnormal Glucose Counterregulation in Insulin-dependent Diabetes Mellitus: Interaction of Anti-Insulin Antibodies and Impaired Glucagon and Epinephrine Secretion

TL;DR: It is concluded that impaired A-cell secretion is the predominant mechanism for the delayed glucose recovery after hypoglycemia in diabetic patients without insulin antibodies and normal epinephrine responses, which appears to be acquired defects that develop subsequent to B-cell failure.
Journal ArticleDOI

Meticulous Prevention of Hypoglycemia Normalizes the Glycemic Thresholds and Magnitude of Most of Neuroendocrine Responses to, Symptoms of, and Cognitive Function During Hypoglycemia in Intensively Treated Patients With Short-Term IDDM

TL;DR: It is concluded that hypoglycemia unawareness in IDDM is largely reversible and that intensive insulin therapy and a program of intensive education may substantially prevent hypoglyCEmia and at the same time maintain the glycemic targets of intensive insulin Therapy, at least in patients with IDDM of short duration.
Journal ArticleDOI

Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes First two cases

TL;DR: A phase 1 pilot clinical trial of microencapsulated TX into 10 nonimmunosuppressed patients with type 1 diabetes, under permission and surveillance by the Italian Ministry of Health is initiated.